Hepatobiliary Cancers Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewHepatobiliary cancers are highly lethal. In 2008, approximately 21,370 persons in the United States were estimated to be diagnosed with liver or intrahepatic bile duct cancer and 9520 with gallbladder cancer or other biliary tract cancer. Furthermore, approximately 18,410 deaths from liver or intrahepatic bile duct cancer and 3340 deaths from gallbladder cancer or other biliary tract cancer were estimated to occur.1The types of hepatobiliary cancers covered in these guidelines include hepatocellular carcinoma (HCC), gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. By definition, these guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Although not explicitly stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option for treatment of hepatobiliary cancers.HCCRisk Factors and...

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 2

    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S3550.

    • Search Google Scholar
    • Export Citation
  • 3

    Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271285.

  • 4

    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:12081236.

  • 5

    Di Bisceglie AM, Lyra AC, Schwartz M. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98:20602063.

    • Search Google Scholar
    • Export Citation
  • 6

    Marchesini G, Bugianesi E, Forlani G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917923.

  • 7

    Takamatsu S, Noguchi N, Kudoh A. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008;55:609614.

    • Search Google Scholar
    • Export Citation
  • 8

    Bartlett DL, Di Bisceglie AM, Dawson LA. Cancer of the liver. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:11291156.

    • Search Google Scholar
    • Export Citation
  • 9

    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507539.

  • 10

    Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep 2008;10:6066.

  • 11

    Lok AS, Seeff LB, Morgan TR. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138148.

    • Search Google Scholar
    • Export Citation
  • 12

    Yeoman AD, Al-Chalabi T, Karani JB. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48:863870.

    • Search Google Scholar
    • Export Citation
  • 13

    Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol 2006;20:257260.

    • Search Google Scholar
    • Export Citation
  • 14

    Ichikawa T, Yanagi K, Motoyoshi Y. Two cases of nonalcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis. J Gastroenterol Hepatol 2006;21:18651866.

    • Search Google Scholar
    • Export Citation
  • 15

    Guzman G, Brunt EM, Petrovic LM. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:17611766.

    • Search Google Scholar
    • Export Citation
  • 16

    Department of Health and Human Services Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Available at: www.cdc.gov/nchs/data/nhanes/databriefs/viralhep.pdf. Accessed February 19, 2009.

    • Search Google Scholar
    • Export Citation
  • 17

    Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997;1:559568.

  • 18

    Ryder SD, Irving WL, Jones DA. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451455.

    • Search Google Scholar
    • Export Citation
  • 19

    Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34 Suppl 1:S13.

  • 20

    Goldstein ST, Zhou F, Hadler SC. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:13291339.

    • Search Google Scholar
    • Export Citation
  • 21

    Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2:11291133.

    • Search Google Scholar
    • Export Citation
  • 22

    Younossi ZM. Review article: current management of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:212.

    • Search Google Scholar
    • Export Citation
  • 23

    Sanyal AJ, Banas C, Sargeant C. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43:682689.

    • Search Google Scholar
    • Export Citation
  • 24

    Yatsuji S, Hashimoto E, Tobari M. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2008;24:248254.

    • Search Google Scholar
    • Export Citation
  • 25

    Asare GA, Bronz M, Naidoo V, Kew MC. Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic mutagenesis. Toxicology 2008;254:1118.

    • Search Google Scholar
    • Export Citation
  • 26

    Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 2007;41:761772.

  • 27

    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417422.

  • 28

    Chang PE, Ong WC, Lui HF, Tan CK. Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol 2008;43:881888.

    • Search Google Scholar
    • Export Citation
  • 29

    El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:17521763.

  • 30

    Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999;6:108110.

    • Search Google Scholar
    • Export Citation
  • 31

    Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969977.

  • 32

    Bruix J, Sherman M, Llovet JM. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421430.

    • Search Google Scholar
    • Export Citation
  • 33

    Miller G, Schwartz LH, D’Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am 2007;16:343368.

    • Search Google Scholar
    • Export Citation
  • 34

    Marrero JA, Hussain HK, Nghiem HV. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005;11:281289.

    • Search Google Scholar
    • Export Citation
  • 35

    Forner A, Vilana R, Ayuso C. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97104.

    • Search Google Scholar
    • Export Citation
  • 36

    Torzilli G, Minagawa M, Takayama T. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999;30:889893.

    • Search Google Scholar
    • Export Citation
  • 37

    Levy I, Greig PD, Gallinger S. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg 2001;234:206209.

  • 38

    Durazo FA, Blatt LM, Corey WG. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:15411548.

    • Search Google Scholar
    • Export Citation
  • 39

    Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 2008;395:1926.

    • Search Google Scholar
    • Export Citation
  • 40

    Katyal S, Oliver JH III, Peterson MS. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698703.

  • 41

    Natsuizaka M, Omura T, Akaike T. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005;20:17811787.

    • Search Google Scholar
    • Export Citation
  • 42

    Cooper GS, Bellamy P, Dawson NV. A prognostic model for patients with end-stage liver disease. Gastroenterology 1997;113:12781288.

  • 43

    Pugh RN, Murray-Lyon IM, Dawson JL. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646649.

  • 44

    Cholongitas E, Papatheodoridis GV, Vangeli M. Systematic review: the model for end-stage liver disease--should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005;22:10791089.

    • Search Google Scholar
    • Export Citation
  • 45

    Bruix J, Castells A, Bosch J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:10181022.

    • Search Google Scholar
    • Export Citation
  • 46

    Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004;39:280282.

    • Search Google Scholar
    • Export Citation
  • 47

    Boyer TD. Changing clinical practice with measurements of portal pressure. Hepatology 2004;39:283285.

  • 48

    Thalheimer U, Mela M, Patch D, Burroughs AK. Targeting portal pressure measurements: a critical reappraisal. Hepatology 2004;39:286290.

  • 49

    Malinchoc M, Kamath PS, Gordon FD. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864871.

    • Search Google Scholar
    • Export Citation
  • 50

    Martin AP, Bartels M, Hauss J, Fangmann J. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc 2007;39:31693174.

    • Search Google Scholar
    • Export Citation
  • 51

    Eggel H. Uber das primare Carcinoma der Leber. Beitr Pathol Anat Allg Pathol 1901;30:506604.

  • 52

    Clavien PA, Fong Y, Lyerly HK. Malignant Liver Tumors: Current and Emerging Therapies. 2nd ed. Sudbury: Jones and Barlett; 2003.

  • 53

    Yuki K, Hirohashi S, Sakamoto M. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990;66:21742179.

    • Search Google Scholar
    • Export Citation
  • 54

    Dohmen K. Many staging systems for hepatocellular carcinoma: evolution from Child-Pugh, Okuda to SLiDe. J Gastroenterol Hepatol 2004;19:12271232.

    • Search Google Scholar
    • Export Citation
  • 55

    Marrero JA, Fontana RJ, Barrat A. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707716.

    • Search Google Scholar
    • Export Citation
  • 56

    Kamath PS, Wiesner RH, Malinchoc M. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464470.

  • 57

    Greene F, Page D, Fleming I, Fritz A. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.

  • 58

    Okuda K, Ohtsuki T, Obata H. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918928.

    • Search Google Scholar
    • Export Citation
  • 59

    Chevret S, Trinchet JC, Mathieu D. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999;31:133141.

    • Search Google Scholar
    • Export Citation
  • 60

    Leung TW, Tang AM, Zee B. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94:17601769.

    • Search Google Scholar
    • Export Citation
  • 61

    Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207215.

    • Search Google Scholar
    • Export Citation
  • 62

    The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751755.

    • Search Google Scholar
    • Export Citation
  • 63

    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329338.

  • 64

    Omagari K, Honda S, Kadokawa Y. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:805811.

    • Search Google Scholar
    • Export Citation
  • 65

    Huo TI, Lin HC, Huang YH. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006;107:141148.

    • Search Google Scholar
    • Export Citation
  • 66

    Limquiaco JL, Wong GL, Wong VW. Evaluation of Model for End Stage Liver Disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. J Gastroenterol Hepatol 2008;24:6369.

    • Search Google Scholar
    • Export Citation
  • 67

    Nanashima A, Sumida Y, Abo T. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol 2006;41:250256.

    • Search Google Scholar
    • Export Citation
  • 68

    Wang JH, Changchien CS, Hu TH. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma—survival analysis of 3892 patients. Eur J Cancer 2008;44:10001006.

    • Search Google Scholar
    • Export Citation
  • 69

    Vauthey JN, Ribero D, Abdalla EK. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 2007;204:10161027; discussion 1027–1018.

    • Search Google Scholar
    • Export Citation
  • 70

    Huitzil FD, Capanu M, O’Reilly E. Ranking and improvement of staging systems in advanced hepatocellular carcinoma [abstract]. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, Florida. Abstract 210.

    • Search Google Scholar
    • Export Citation
  • 71

    Cho YK, Chung JW, Kim JK. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 2008;112:352361.

    • Search Google Scholar
    • Export Citation
  • 72

    Collette S, Bonnetain F, Paoletti X. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 2008;19:11171126.

    • Search Google Scholar
    • Export Citation
  • 73

    Guglielmi A, Ruzzenente A, Pachera S. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008;103:597604.

    • Search Google Scholar
    • Export Citation
  • 74

    Cho CS, Gonen M, Shia J. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg 2008;206:281291.

    • Search Google Scholar
    • Export Citation
  • 75

    Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol 2008;26:58455848.

  • 76

    Pawlik TM, Poon RT, Abdalla EK. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450457; discussion 457–458.

    • Search Google Scholar
    • Export Citation
  • 77

    Chok KS, Ng KK, Poon RT. Impact of postoperative complications on long-term outcome of curative resection for hepatocellular carcinoma. Br J Surg 2009;96:8187.

    • Search Google Scholar
    • Export Citation
  • 78

    Kianmanesh R, Regimbeau JM, Belghiti J. Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surg Oncol Clin N Am 2003;12:5163.

    • Search Google Scholar
    • Export Citation
  • 79

    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:14341440.

    • Search Google Scholar
    • Export Citation
  • 80

    Poon RT, Fan ST, Lo CM. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373382.

    • Search Google Scholar
    • Export Citation
  • 81

    Seo DD, Lee HC, Jang MK. Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization. Ann Surg Oncol 2007;14:35013509.

    • Search Google Scholar
    • Export Citation
  • 82

    Wei AC, Tung-Ping Poon R. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 2003;90:3341.

    • Search Google Scholar
    • Export Citation
  • 83

    Ribero D, Curley SA, Imamura H. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol 2008;15:966992.

    • Search Google Scholar
    • Export Citation
  • 84

    Tsai TJ, Chau GY, Lui WY. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000;127:603608.

    • Search Google Scholar
    • Export Citation
  • 85

    Abdalla EK, Denys A, Hasegawa K. Treatment of large and advanced hepatocellular carcinoma. Ann Surg Oncol 2008;15:979985.

  • 86

    Jonas S, Bechstein WO, Steinmuller T. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:10801086.

    • Search Google Scholar
    • Export Citation
  • 87

    Vauthey JN, Lauwers GY, Esnaola NF. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:15271536.

  • 88

    Yamakado K, Nakatsuka A, Takaki H. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008;247:260266.

    • Search Google Scholar
    • Export Citation
  • 89

    Kubota K, Makuuchi M, Kusaka K. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997;26:11761181.

    • Search Google Scholar
    • Export Citation
  • 90

    Shoup M, Gonen M, D’Angelica M. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7:325330.

    • Search Google Scholar
    • Export Citation
  • 91

    Farges O, Belghiti J, Kianmanesh R. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208217.

    • Search Google Scholar
    • Export Citation
  • 92

    Mazzaferro V, Regalia E, Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693699.

    • Search Google Scholar
    • Export Citation
  • 93

    Mazzaferro V, Chun YS, Poon RT. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008;15:10011007.

  • 94

    United Network for Organ Sharing: Organ Donation and Transplantation. Available at: www.unos.org. Accessed February 19, 2009.

  • 95

    Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000;31:10191021.

    • Search Google Scholar
    • Export Citation
  • 96

    Facciuto ME, Koneru B, Rocca JP. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol 2008;15:13831391.

    • Search Google Scholar
    • Export Citation
  • 97

    Poon RT. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection? Ann Surg Oncol 2007;14:541547.

    • Search Google Scholar
    • Export Citation
  • 98

    Poon RT, Fan ST, Lo CM. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007;245:5158.

    • Search Google Scholar
    • Export Citation
  • 99

    Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl 2007;13:15151520.

    • Search Google Scholar
    • Export Citation
  • 100

    Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134:13421351.

    • Search Google Scholar
    • Export Citation
  • 101

    Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839846.

    • Search Google Scholar
    • Export Citation
  • 102

    Duffy JP, Vardanian A, Benjamin E. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502509; discussion 509–511.

    • Search Google Scholar
    • Export Citation
  • 103

    Yao FY, Ferrell L, Bass NM. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:13941403.

    • Search Google Scholar
    • Export Citation
  • 104

    Volk M, Marrero JA. Liver transplantation for hepatocellular carcinoma: who benefits and who is harmed? Gastroenterology 2008;134:16121614.

    • Search Google Scholar
    • Export Citation
  • 105

    Lee SG, Hwang S, Moon DB. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008;14:935945.

    • Search Google Scholar
    • Export Citation
  • 106

    Yao FY, Xiao L, Bass NM. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:25872596.

    • Search Google Scholar
    • Export Citation
  • 107

    Llovet JM, Di Bisceglie AM, Bruix J. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698711.

    • Search Google Scholar
    • Export Citation
  • 108

    Pompili M, Mirante VG, Rondinara G. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005;11:11171126.

    • Search Google Scholar
    • Export Citation
  • 109

    Mazzaferro V, Battiston C, Perrone S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900909.

    • Search Google Scholar
    • Export Citation
  • 110

    Richard HM III, Silberzweig JE, Mitty HA. Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma. Radiology 2000;214:775779.

    • Search Google Scholar
    • Export Citation
  • 111

    Kulik LM, Atassi B, van Holsbeeck L. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94:572586.

    • Search Google Scholar
    • Export Citation
  • 112

    Vivarelli M, Guglielmi A, Ruzzenente A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004;240:102107.

    • Search Google Scholar
    • Export Citation
  • 113

    Lin SM, Lin CJ, Lin CC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:11511156.

    • Search Google Scholar
    • Export Citation
  • 114

    Chen MS, Li JQ, Zheng Y. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321328.

    • Search Google Scholar
    • Export Citation
  • 115

    Livraghi T, Goldberg SN, Lazzaroni S. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000;214:761768.

    • Search Google Scholar
    • Export Citation
  • 116

    Livraghi T, Meloni F, Di Stasi M. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:8289.

    • Search Google Scholar
    • Export Citation
  • 117

    Lin SM, Lin CJ, Lin CC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:17141723.

    • Search Google Scholar
    • Export Citation
  • 118

    Brunello F, Veltri A, Carucci P. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008;43:727735.

    • Search Google Scholar
    • Export Citation
  • 119

    Shiina S, Teratani T, Obi S. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122130.

    • Search Google Scholar
    • Export Citation
  • 120

    Yan K, Chen MH, Yang W. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol 2008;67:336347.

    • Search Google Scholar
    • Export Citation
  • 121

    Choi D, Lim HK, Rhim H. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 2007;17:684692.

    • Search Google Scholar
    • Export Citation
  • 122

    Sala M, Llovet JM, Vilana R. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:13521360.

    • Search Google Scholar
    • Export Citation
  • 123

    Maluccio M, Covey AM, Gandhi R. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol 2005;16:955961.

    • Search Google Scholar
    • Export Citation
  • 124

    Maluccio MA, Covey AM, Porat LB. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008;19:862869.

    • Search Google Scholar
    • Export Citation
  • 125

    Kulik LM, Carr BI, Mulcahy MF. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:7181.

    • Search Google Scholar
    • Export Citation
  • 126

    Llovet JM, Real MI, Montana X. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:17341739.

    • Search Google Scholar
    • Export Citation
  • 127

    Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S211221.

  • 128

    O’Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist 2007;12:14251432.

    • Search Google Scholar
    • Export Citation
  • 129

    Lo CM, Ngan H, Tso WK. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:11641171.

    • Search Google Scholar
    • Export Citation
  • 130

    Stuart K, Stokes K, Jenkins R. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 1993;72:32023209.

    • Search Google Scholar
    • Export Citation
  • 131

    Llado L, Virgili J, Figueras J. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88:5057.

    • Search Google Scholar
    • Export Citation
  • 132

    Doan PL, O’Neil BH, Moore DT, Bernard SA. Predictors of survival in patients with hepatocellular carcinoma treated with transarterial chemoembolization [abstract]. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, Florida. Abstract 204.

    • Search Google Scholar
    • Export Citation
  • 133

    Molinari M, Dixon E, Kachura JR. Chemoembolization for unresectable hepatocellular carcinoma? Presented at the 2004 Gastrointestinal Cancers Symposium; January 22–24, 2004; Orlando, Florida. Abstract 167.

    • Search Google Scholar
    • Export Citation
  • 134

    Ibrahim SM, Lewandowski RJ, Sato KT. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008;14:16641669.

    • Search Google Scholar
    • Export Citation
  • 135

    Atassi B, Bangash AK, Bahrani A. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008;28:8199.

    • Search Google Scholar
    • Export Citation
  • 136

    Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:16531663.

  • 137

    Ikeda M, Okusaka T, Ueno H. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 2007;72:188193.

    • Search Google Scholar
    • Export Citation
  • 138

    Thomas MB, O’Beirne JP, Furuse J. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008;15:10081014.

    • Search Google Scholar
    • Export Citation
  • 139

    Yeo W, Mok TS, Zee B. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:15321538.

    • Search Google Scholar
    • Export Citation
  • 140

    Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378390.

  • 141

    Cheng A, Kang YK, Chen CL. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4509.

    • Search Google Scholar
    • Export Citation
  • 142

    Abou-Alfa GK, Schwartz L, Ricci S. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:42934300.

    • Search Google Scholar
    • Export Citation
  • 143

    Raoul JL, Santoro A, Beaugrand M. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4587.

    • Search Google Scholar
    • Export Citation
  • 144

    Craxi A, Porta C, Sangiovanni A. Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: a sub-analysis from the SHARP trial [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 15591.

    • Search Google Scholar
    • Export Citation
  • 145

    Bolondi L, Caspary J, Bennouna B. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma: subgroup analysis of the SHARP trial [abstract]. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, Florida. Abstract 129.

    • Search Google Scholar
    • Export Citation
  • 146

    Abou-Alfa G, Amadori D, Santoro A. Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis? [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4518.

    • Search Google Scholar
    • Export Citation
  • 147

    Miller AA, Murry DJ, Owzar K. Pharmacokinetic and phase I study of sorafenib for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction: CALGB 60301 [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 3538.

    • Search Google Scholar
    • Export Citation
  • 148

    Yau T, Chan P, Ng KK. Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 15513.

    • Search Google Scholar
    • Export Citation
  • 149

    Bartlett DL, Ramanthan RK, Ben-Josef E. Cancers of the biliary tree. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 8th ed: Wolters Kluwer; Lippincott Williams & Wilkins; 2008:11561186.

    • Search Google Scholar
    • Export Citation
  • 150

    Petrowsky H, Wildbrett P, Husarik DB. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:4350.

    • Search Google Scholar
    • Export Citation
  • 151

    Corvera CU, Blumgert LH, Akhurst T. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008;206:5765.

    • Search Google Scholar
    • Export Citation
  • 152

    Duffy A, Capanu M, Abou-Alfa GK. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 2008;98:485489.

    • Search Google Scholar
    • Export Citation
  • 153

    Jarnagin WR, Ruo L, Little SA. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:16891700.

    • Search Google Scholar
    • Export Citation
  • 154

    Donohue JH, Stewart AK, Menck HR. The National Cancer Data Base report on carcinoma of the gallbladder, 1989–1995. Cancer 1998;83:26182628.

    • Search Google Scholar
    • Export Citation
  • 155

    D’Angelica M, Dalal KM, Dematteo RP. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol, in press.

  • 156

    Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 2007;11:671681.

    • Search Google Scholar
    • Export Citation
  • 157

    Jensen EH, Abraham A, Habermann EB. A critical analysis of the surgical management of early-stage gallbladder cancer in the United States. J Gastrointest Surg 2008; in press.

    • Search Google Scholar
    • Export Citation
  • 158

    Daines WP, Rajagopalan V, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, part 2. Oncology (Williston Park) 2004;18:10491059; discussion 1060, 1065–1046, 1068.

    • Search Google Scholar
    • Export Citation
  • 159

    Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006;45:856867.

  • 160

    Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:3342.

  • 161

    DeOliveira ML, Cunningham SC, Cameron JL. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755762.

    • Search Google Scholar
    • Export Citation
  • 162

    Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999;10(Suppl 4):308311.

  • 163

    Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, part 1. Oncology (Williston Park) 2004;18:889896.

    • Search Google Scholar
    • Export Citation
  • 164

    Yamamoto S, Kubo S, Hai S. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004;95:592595.

  • 165

    Endo I, Gonen M, Yopp AC. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:8496.

    • Search Google Scholar
    • Export Citation
  • 166

    Kim JY, Kim MH, Lee TY. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008;103:11451151.

    • Search Google Scholar
    • Export Citation
  • 167

    Seo S, Hatano E, Higashi T. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 2008;143:769777.

    • Search Google Scholar
    • Export Citation
  • 168

    Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol 2003;181:819827.

    • Search Google Scholar
    • Export Citation
  • 169

    Lim JH, Park CK. Pathology of cholangiocarcinoma. Abdom Imaging 2004;29:540547.

  • 170

    Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003;10:288291.

  • 171

    Pawlik TM, Nathan H, Aloia T. A simplified staging system for intrahepatic cholangiocarcinoma [abstract]. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, Florida. Abstract 194.

    • Search Google Scholar
    • Export Citation
  • 172

    Jarnagin WR, Fong Y, DeMatteo RP. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507517; discussion 517–509.

    • Search Google Scholar
    • Export Citation
  • 173

    Lieser MJ, Barry MK, Rowland C. Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 1998;5:4147.

    • Search Google Scholar
    • Export Citation
  • 174

    Yeh CN, Jan YY, Yeh TS. Hepatic resection of the intraductal papillary type of peripheral cholangiocarcinoma. Ann Surg Oncol 2004;11:606611.

    • Search Google Scholar
    • Export Citation
  • 175

    Nakagohri T, Asano T, Kinoshita H. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 2003;27:289293.

    • Search Google Scholar
    • Export Citation
  • 176

    Isaji S, Kawarada Y, Taoka H. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 1999;6:108116.

    • Search Google Scholar
    • Export Citation
  • 177

    Berdah SV, Delpero JR, Garcia S. A Western surgical experience of peripheral cholangiocarcinoma. Br J Surg 1996;83:15171521.

  • 178

    Silva MA, Tekin K, Aytekin F. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005;31:533539.

    • Search Google Scholar
    • Export Citation
  • 179

    Havlik R, Sbisa E, Tullo A. Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors. Hepatogastroenterology 2000;47:927931.

    • Search Google Scholar
    • Export Citation
  • 180

    Cherqui D, Benoist S, Malassagne B. Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg 2000;135:302308.

    • Search Google Scholar
    • Export Citation
  • 181

    Hochwald SN, Burke EC, Jarnagin WR. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999;134:261266.

    • Search Google Scholar
    • Export Citation
  • 182

    Heimbach JK, Haddock MG, Alberts SR. Transplantation for hilar cholangiocarcinoma. Liver Transpl 2004;10:S6568.

  • 183

    Sudan D, DeRoover A, Chinnakotla S. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002;2:774779.

    • Search Google Scholar
    • Export Citation
  • 184

    Rea DJ, Heimbach JK, Rosen CB. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451458; discussion 458–461.

    • Search Google Scholar
    • Export Citation
  • 185

    Davids PH, Groen AK, Rauws EA. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:14881492.

    • Search Google Scholar
    • Export Citation
  • 186

    Prat F, Chapat O, Ducot B. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998;47:17.

    • Search Google Scholar
    • Export Citation
  • 187

    Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002;56:835841.

    • Search Google Scholar
    • Export Citation
  • 188

    American Society for Gastrointestinal Endoscopy Technology Status Report. Photodynamic therapy for gastrointestinal disease. Gastrointest Endosc 2006;63:927932.

    • Search Google Scholar
    • Export Citation
  • 189

    Dumoulin FL, Gerhardt T, Fuchs S. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003;57:860867.

    • Search Google Scholar
    • Export Citation
  • 190

    Ortner ME, Caca K, Berr F. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125:13551363.

    • Search Google Scholar
    • Export Citation
  • 191

    Zoepf T, Jakobs R, Arnold JC. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005;100:24262430.

    • Search Google Scholar
    • Export Citation
  • 192

    Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008;13:415423.

  • 193

    Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol 2007;96:813.

    • Search Google Scholar
    • Export Citation
  • 194

    Kayahara M, Nagakawa T. Recent trends of gallbladder cancer in Japan: an analysis of 4,770 patients. Cancer 2007;110:572580.

  • 195

    Takada T, Amano H, Yasuda H. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:16851695.

    • Search Google Scholar
    • Export Citation
  • 196

    Macdonald OK, Crane CH. Palliative and postoperative radiotherapy in biliary tract cancer. Surg Oncol Clin N Am 2002;11:941954.

  • 197

    Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006;20:873884; discussion 886–878, 893–875.

    • Search Google Scholar
    • Export Citation
  • 198

    Nelson JW, Ghafoori AP, Willett CG. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009;73:148153.

    • Search Google Scholar
    • Export Citation
  • 199

    Hughes MA, Frassica DA, Yeo CJ. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178182.

    • Search Google Scholar
    • Export Citation
  • 200

    Wang SJ, Fuller CD, Kim JS. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol 2008;26:21122117.

    • Search Google Scholar
    • Export Citation
  • 201

    Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008;72:14951501.

    • Search Google Scholar
    • Export Citation
  • 202

    Borghero Y, Crane CH, Szklaruk J. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008;15:31473156.

    • Search Google Scholar
    • Export Citation
  • 203

    Lim K, Oh E, Chie E. Which is better in patients with curatively resected extrahepatic biliary tract cancer? Adjuvant concurrent chemoradiation alone versus CCRT followed by maintenance chemotherapy [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 15659.

    • Search Google Scholar
    • Export Citation
  • 204

    Das P, Wolff RA, Abbruzzese JL. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol 2006;1:41.

  • 205

    Lin LL, Picus J, Drebin JA. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol 2005;28:234241.

    • Search Google Scholar
    • Export Citation
  • 206

    Glimelius B, Hoffman K, Sjoden PO. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593600.

    • Search Google Scholar
    • Export Citation
  • 207

    Rao S, Cunningham D, Hawkins RE. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005;92:16501654.

    • Search Google Scholar
    • Export Citation
  • 208

    Kim TW, Chang HM, Kang HJ. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:11151120.

    • Search Google Scholar
    • Export Citation
  • 209

    Doval DC, Sekhon JS, Gupta SK. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:15161520.

    • Search Google Scholar
    • Export Citation
  • 210

    Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005;16:279281.

    • Search Google Scholar
    • Export Citation
  • 211

    Knox JJ, Hedley D, Oza A. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:23322338.

    • Search Google Scholar
    • Export Citation
  • 212

    Koeberle D, Saletti P, Borner M. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008;26:37023708.

    • Search Google Scholar
    • Export Citation
  • 213

    Andre T, Tournigand C, Rosmorduc O. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:13391343.

    • Search Google Scholar
    • Export Citation
  • 214

    Nehls O, Oettle H, Hartmann JT. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309315.

    • Search Google Scholar
    • Export Citation
  • 215

    Kobayashi K, Tsuji A, Morita S. A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and low-dose consecutive (Cisplatin) in advanced biliary tract carcinoma. BMC Cancer 2006;6:121.

    • Search Google Scholar
    • Export Citation
  • 216

    Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896902.

  • 217

    Yonemoto N, Furuse J, Okusaka T. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007;37:843851.

    • Search Google Scholar
    • Export Citation
  • 218

    Kim MJ, Oh DY, Lee SH. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 2008;8:374.

    • Search Google Scholar
    • Export Citation
  • 219

    Alberts SR, Al-Khatib H, Mahoney MR. Gemcitabine, 5-fluorouracil. And leucovorin in advanced biliary tract and gallbladder carcinoma. A North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111118.

    • Search Google Scholar
    • Export Citation
  • 220

    Ghafoori AP, Nelson JW, Willett C. Chemoradiation for inoperable extrahepatic cholangiocarcinoma [abstract]. Presented at the 2008 Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, Florida. Abstract 166.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 631 399 29
PDF Downloads 238 179 9
EPUB Downloads 0 0 0